Cat. No.: HY-146751

PI3K/Akt/mTOR-IN-2

5 Cited Publications

Customer Review

Based on 5 publication(s) in Google Scholar

PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC₅₀ value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis.

For research use only. We do not sell to patients.

Purity: 99.93%
CAS No.: 2757804-89-8
Formula: C₁₇H₁₃F₂NO
Molecular Weight:285.29

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

PI3K/Akt/mTOR-IN-2 Chemical Structure

CAS No.: 2757804-89-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (5)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC₅₀: 2.29 μM (PI3K/AKT/mTOR) in MDA-MB-231^[1]

All PI3K Isoforms :

All Akt Isoforms :

All mTOR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	14.81 μM Compound: 23	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34990979]
BGC-823	IC₅₀	9.11 μM Compound: 23	Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34990979]
MCF-10A	IC₅₀	24.63 μM Compound: 23	Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34990979]
MCF7	IC₅₀	7.89 μM Compound: 23	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34990979]
MDA-MB-231	IC₅₀	2.29 μM Compound: 23	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34990979]
PC-3	IC₅₀	9.04 μM Compound: 23	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34990979]

In Vitro

PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 hours) exhibits effective anti-cancer activity with IC₅₀s of 2.29 - 24.63 μM, of which, IC₅₀ in MDA-MB-231 is 2.29 μM^[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1^[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners^[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells^[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca²⁺^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:

PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells^[1]
Concentration:

0.5 - 100 μM
Incubation Time:

72 hours
Result:

Exhibited effective anti-cancer activity with IC₅₀s of 2.29 - 24.63 μM, of which, IC₅₀ in MDA-MB-231 was 2.29 μM.

Cell Cycle Analysis

Cell Line:

MDA-MB-231^[1]
Concentration:

1 μM, 2 μM and 4 μM
Incubation Time:

24 hours
Result:

Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1.

Apoptosis Analysis

Cell Line:

MDA-MB-231^[1]
Concentration:

1 μM, 2 μM and 4 μM
Incubation Time:

24, 48 and 72 hours
Result:

Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners.

Western Blot Analysis

Cell Line:

MDA-MB-231^[1]
Concentration:

1 μM, 2 μM and 4 μM
Incubation Time:

48 hours
Result:

Increased the expression of Bax, and decreased the expression of Bcl-2

Chemical Information

CAS No. 2757804-89-8
Appearance Solid
Molecular Weight 285.29
Formula C₁₇H₁₃F₂NO
Color White to off-white
SMILES

FC1=CC(F)=CC(C2OCCC3=C2NC4=C3C=CC=C4)=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All

Sort by:

Journal Impact Factor

Stem Cell Res Ther

Extrachromosomal circular DNAs in the differentiation of human bone marrow mesenchymal stem cells. [Abstract]

2025 Jul 18;16(1):383. PMID: 40682088
Biochim Biophys Acta Mol Basis Dis

UHMK1 regulates VM formation in OSCC by interacting with STMN1. [Abstract]

2026 Aug;1872(6):168257. PMID: 41966283
Tissue Cell

Elucidating the mechanism of IL-1β-Mediated Piezo1 expression regulation of chondrocyte autophagy and apoptosis via the PI3K/AKT/mTOR signaling Pathway. [Abstract]

2024 Feb:86:102291. PMID: 38134572
Crit Rev Eukaryot Gene Expr

Transplantation of miR-193b-3p-Transfected BMSCs Improves Neurological Impairment after Traumatic Brain Injury through S1PR3-Mediated Regulation of the PI3K/AKT/mTOR Signaling Pathway. [Abstract]

2024;34(7):1-16. PMID: 39072405
Research Square Print

January 4th, 2023.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (350.52 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5052 mL

17.5260 mL

35.0521 mL

5 mM

0.7010 mL

3.5052 mL

7.0104 mL

10 mM

0.3505 mL

1.7526 mL

3.5052 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Qin J, Sun X, Ma Y, et al. Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway [published online ahead of print, 2021 Dec [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5052 mL	17.5260 mL	35.0521 mL	87.6301 mL
	5 mM	0.7010 mL	3.5052 mL	7.0104 mL	17.5260 mL
	10 mM	0.3505 mL	1.7526 mL	3.5052 mL	8.7630 mL
	15 mM	0.2337 mL	1.1684 mL	2.3368 mL	5.8420 mL
	20 mM	0.1753 mL	0.8763 mL	1.7526 mL	4.3815 mL
	25 mM	0.1402 mL	0.7010 mL	1.4021 mL	3.5052 mL
	30 mM	0.1168 mL	0.5842 mL	1.1684 mL	2.9210 mL
	40 mM	0.0876 mL	0.4382 mL	0.8763 mL	2.1908 mL
	50 mM	0.0701 mL	0.3505 mL	0.7010 mL	1.7526 mL
	60 mM	0.0584 mL	0.2921 mL	0.5842 mL	1.4605 mL
	80 mM	0.0438 mL	0.2191 mL	0.4382 mL	1.0954 mL
	100 mM	0.0351 mL	0.1753 mL	0.3505 mL	0.8763 mL

Keywords

PI3K/Akt/mTOR-IN-2

5 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PI3K/Akt/mTOR-IN-2

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) PI3K/Akt/mTOR-IN-2

All PI3K Isoforms

All Akt Isoforms

All mTOR Isoforms

Biological Activity

Chemical Information

Publications (5)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

PI3K/Akt/mTOR-IN-2 Related Classifications

HY-146751 Related Classifications